- Age-related macular degeneration is the leading cause of irreversible central vision loss in adults over 50, and most people in the early stages have no symptoms at all.
- Changes to the retina are detectable on a scan long before you notice anything wrong, which is why your doctor may flag a concern even when your vision feels normal.
- Dry AMD progresses slowly over years. Wet AMD can cause significant vision distortion within weeks and needs urgent treatment.
- The stage you are at determines how often you need monitoring and whether AMD treatment is required.
- Caught early, AMD is manageable. Left undetected, the options narrow.
You went for a routine eye check expecting a minor prescription update. Instead, your doctor lingered over the retinal scan, mentioned your macula, and asked you to come back for further imaging. Afterwards, you drove yourself home without any trouble. The whole thing felt a little unnecessary.
It was not. The macula is the part of your eye responsible for reading, recognising faces, and seeing fine detail. It can deteriorate quietly for years before you notice any change at all. Your doctor was not being overcautious. They were looking at something your vision had not yet told you about.
What Is the Macula, and Why Does It Matter?
The macula in plain language
LASIK is one of the most widely performed laser eye surgery procedures globally. A femtosecond laser creates a thin hinged flap in the cornea, the flap is lifted, an excimer laser reshapes the underlying stromal tissue, and the flap is repositioned. The entire procedure takes approximately 10 to 15 minutes per eye.
The cells densely packed into the macula, particularly in its very centre (the fovea), are not replaceable. When they are damaged or lost, that part of your visual field goes with them.
Central vision loss is immediately and significantly disabling. People with advanced macular disease can navigate a room using their side vision, but they cannot read a menu, recognise a friend’s expression, or see a face clearly.
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over 50 in developed countries. Studies projected that approximately 196 million people would be affected by AMD globally by 2020, rising to 288 million by 2040 (Wong et al., 2014, Lancet Global Health).
In Singapore, data from a Singapore Epidemiology of Eye Diseases (SEED) Study indicates AMD prevalence increases sharply with age, particularly in those over 60 (Cheung et al., 2014, Ophthalmology).
Dry AMD: the silent early stage
At this stage, small deposits called drusen (protein and lipid waste beneath the retina) form under the retinal pigment epithelium. A retinal scan can detect drusen clearly, even when they are too small and too few to cause any perceptible change in vision.
Many patients with early dry AMD have no complaints at all. They read without difficulty. They pass vision screenings. The drusen, however, is there on the scan.
Your specialist may give you an Amsler grid, a simple grid of straight lines with a dot in the centre, as a home monitoring tool. If the lines appear wavy or distorted, or if a section of the grid is missing, contact your eye doctor promptly.
What Is the Macula, and Why Does It Matter?
The OCT scan explained
Drusen appear as bumps beneath the retinal pigment epithelium layer. Retinal thinning shows up as a reduction in layer thickness. In wet AMD, OCT reveals fluid accumulation: pockets of liquid that indicate abnormal blood vessel activity and directly inform how urgently intervention is needed.
At Angel Eye & Cataract Centre, retinal imaging uses the ZEISS CIRRUS PathFinder, an AI-guided OCT image assessment tool trained on over 75,000 OCT B-scan images.
It analyses each eye scan, assesses image quality, and highlights areas requiring the surgeon’s further attention, supporting Dr Allan Fong in detecting macular changes that might otherwise go unnoticed.
Staging AMD: early vs intermediate vs late
| Stage | Key features | Typical monitoring frequency |
| Early | Small drusen; vision usually unaffected | Annually |
| Intermediate | Larger drusen; possible retinal pigment epithelium changes; mild low-light difficulty in some patients | Every six months |
| Late (dry) | Geographic atrophy with central involvement | As directed by specialist |
| Late (wet) | Abnormal blood vessel growth; fluid accumulation | Immediate treatment; ongoing OCT-guided review |
When Dry AMD Becomes Wet AMD: Why the Timeline Suddenly Matters
The MARINA trial demonstrated that ranibizumab, administered promptly, prevented vision loss and produced mean visual acuity gains over two years, outcomes that are harder to achieve once extensive retinal damage has occurred (Rosenfeld et al., 2006, New England Journal of Medicine).
Two symptoms in particular warrant same-day contact with your retina specialist in Singapore.
- Straight lines that appear wavy, bent, or curved (metamorphopsia). A door frame that looks bent, text on a page seems to ripple, etc.
- A dark or blurry patch developing in the centre of your vision, not at the edges (central scotoma)
Both warrant same-day contact. The OCT scan your specialist performs will confirm whether new fluid is present, and treatment can begin quickly if it is.
How Is AMD Treated in Singapore Today?
AMD treatment varies significantly depending on whether you have the dry or wet form.
| Dry AMD | Wet AMD | |
| Primary treatment | No approved treatment to reverse progression | Intravitreal anti-VEGF injection (agent selected by your specialist) |
| Supplementation | AREDS/AREDS2 formulation for intermediate stage | AREDS/AREDS2 alongside injections |
| Monitoring | Annual to six-monthly OCT review | OCT-guided, typically monthly then every six to eight weeks |
| Lifestyle | Diet, smoking cessation, UV protection | Diet, smoking cessation, UV protection |
| Prognosis | Slow progression; late-stage tissue loss is irreversible | Rapid if untreated; stabilisation possible with prompt treatment, individual outcomes vary |
Anti-VEGF injections for wet AMD
Several anti-VEGF agents are approved for use in wet AMD, each working by inhibiting the VEGF proteins that stimulate neovascularisation and reducing fluid leakage. In many patients, treatment stabilises or modestly improves visual acuity. Your specialist will advise which agent is appropriate for your case.
The procedure sounds more confronting than it is. The eye is anaesthetised with drops. The injection itself takes seconds. Patients typically experience mild pressure and transient floaters; many patients report the procedure as far less uncomfortable than anticipated.
It is performed at the clinic as an outpatient procedure. Treatment frequency varies: monthly injections are common in the early phase, transitioning to every six to eight weeks for many patients, guided by OCT results at each visit.
- Vision that appears suddenly blurry, distorted, or reduced in one eye
- New floaters, flashes of light, or a shadow crossing your central vision
- Any change between injection appointments that feels different from your baseline
If you notice any of these between appointments, contact your specialist the same day rather than waiting for your next scheduled visit.
For dry AMD: monitoring and supplements
The original AREDS (Age-Related Eye Disease Study) formulation, a combination of antioxidant vitamins C and E, beta-carotene, zinc, and copper, was shown to reduce the risk of progression to advanced age-related macular degeneration by approximately 25% in eligible patients (Age-Related Eye Disease Study Research Group, 2001, American Journal of Ophthalmology).
The AREDS2 formulation has since replaced beta-carotene with lutein and zeaxanthin and is now the version most commonly recommended.
Lifestyle factors that may slow progression include a diet rich in leafy green vegetables and oily fish, smoking cessation, and UV protection with quality sunglasses.
What to watch for:
- Lines on your Amsler grid that appear wavy, bowed, or missing
- Increasing difficulty reading in low light or needing brighter conditions than before
- Colours appearing less vivid or contrast seeming reduced in one eye
These changes can be gradual and easy to dismiss. Check each eye separately on your Amsler grid regularly, and flag anything new at your next appointment.
See Clearly: Book a Macular Assessment at Angel Eye & Cataract Centre
For many patients, discovering age-related macular degeneration before symptoms appear is the difference between preserving useful central vision and managing its gradual loss.
If you have been referred for a retinal or macular assessment, or if you have a family history of AMD, book a consultation at Angel Eye & Cataract Centre. Dr Allan Fong will give you a clear picture of where your eyes stand and what to watch for.
References
- Age-Related Eye Disease Study Research Group. (2001). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology, 119(10), 1417–1436. https://doi.org/10.1001/archopht.119.10.1417. PMID: 11594942.
- Age-Related Eye Disease Study 2 Research Group. (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA, 309(19), 2005–2015. https://doi.org/10.1001/jama.2013.4997. PMID: 23644932.
- Cheung, C.M., Li, X., Cheng, C.Y., Zheng, Y., Mitchell, P., Wang, J.J., Wong, T.Y. (2014). Prevalence, racial variations, and risk factors of age-related macular degeneration in Singaporean Chinese, Indians, and Malays. Ophthalmology, 121(8), 1598–1603. https://doi.org/10.1016/j.ophtha.2014.02.004. PMID: 24661862.
- Ferris, F.L., et al. (2013). Clinical classification of age-related macular degeneration. Ophthalmology, 120(4), 844–851. https://doi.org/10.1016/j.ophtha.2012.10.036. PMID: 23332590.
- Rosenfeld, P.J., et al. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1419–1431. https://doi.org/10.1056/NEJMoa054481. PMID: 17021318.
- Wong, W.L., et al. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040. Lancet Global Health, 2(2), e106–e116. https://doi.org/10.1016/S2214-109X(13)70145-1. PMID: 25104651.
